Get started
Work

First-in-human study of the monopolar spindle 1 (Mps1) kinase inhibitor BAY 1161909 in combination with paclitaxel in subjects with advanced malignancies

Year: 2018
Type: article
Study design: Clinical Trial
Abstract: Background: Mps1 is a serine threonine kinase and a core component of the spindle assembly checkpoint. Two potent, selective, and orally active Mps1 inhibitors -- BAY 1161909 (BAY; lead compound) and BAY 1217389 -- have shown improved efficacy in combination with paclitaxel (Pac) in xenograft models, including Pac-insensitive and acquired resistance models. We report here on the safety, tolerability, and maximum tolerated dose (MTD) of the lead compound BAY in combination with Pac.
DOI: 10.1093/annonc/mdy279.410
Authors: P. Lorusso, S.P. Chawla, J. Bendell, A.F. Shields, G. Shapiro, P. Rajagopalan, C. Cyris, I. Bruns, J. Mei, F. Souza, D. Rasco, J.P. Eder, A.W. Tolcher
Institutions: Yale Cancer Center, Yale University, Sarcoma Oncology Center, Tennessee Oncology, The Barbara Ann Karmanos Cancer Institute, Dana-Farber Cancer Institute, South Texas Accelerated Research Therapeutics
Language: English
Subfield: Cell Biology
Open Access status: hybrid
Estimated APC paid: $5,080
OpenAlex ID: W2897057643
FWCI: 0.589
Cites:
Cited by: 12
Related to: 10